The Decipher genomic test could help doctors decide which high-risk prostate cancer patients need abiraterone hormone therapy ...

Three phase 3 prostate cancer results from ESMO 2026 cover long-term survival with abiraterone in metastatic disease, Erleada before and after surgery, and an update on Truqap for PTEN-deficient ...

Adding darolutamide to standard treatment for aggressive prostate cancer reduced the risk of the disease spreading in an ...

With an expected 333,830 new cases in 2026, prostate cancer remains the most common malignancy in men in the United States.  ...

Pfizer’s Talzenna is now the first PARP inhibitor approved by the FDA to treat men with metastatic hormone-sensitive prostate ...

UChicago researchers identify a previously unknown RNA molecule that allows prostate cancer cells to escape targeted ...

A large integrated transcriptomic study shows that rising cancer stemness tracks prostate cancer progression, lineage ...

ASX-listed healthcare companies are advancing new approaches to prostate cancer, spanning imaging, targeted therapies and surgical nerve repair. ... Read More The post ASX healthcare stocks advance ...

Researchers investigating a deadly cancer’s ability to evade treatment have discovered its secret weakness, paving the way ...

Yesterday, the United States Food and Drug Administration (FDA) announced the approval of a new immune-based approach for ...

Please provide your email address to receive an email when new articles are posted on . Prostate cancer screening should begin at age 50, although Black men may need earlier screening. An expert ...